National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002.

[1]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[2]  P. Sorlie,et al.  Trends in Serum Lipids and Lipoproteins of Adults 1960-2002 , 2006 .

[3]  Stephen D. Persell,et al.  Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia , 2006, Journal of general internal medicine.

[4]  Timothy W. Smith,et al.  Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. , 2005, American heart journal.

[5]  David B Lawrence,et al.  Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. , 2005, Diabetes care.

[6]  A. Morris,et al.  Treatment gap in the use of lipid‐lowering drug therapy in diabetes: a population‐based study , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[7]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Folsom.  Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults. , 2003, Circulation.

[9]  Tomás Pantoja,et al.  Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22. , 2003 .

[10]  G. Mensah,et al.  Serum Total Cholesterol Concentrations and Awareness, Treatment, and Control of Hypercholesterolemia Among US Adults: Findings From the National Health and Nutrition Examination Survey, 1999 to 2000 , 2003, Circulation.

[11]  C. Ballantyne,et al.  Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. , 2003, The American journal of cardiology.

[12]  R. Collins,et al.  MRC/BHF Heart Protection Study , 2002, The Lancet.

[13]  G. L’italien,et al.  Primary prevention lipid-lowering drug therapy. , 2002, Circulation.

[14]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[15]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[16]  R. Straka,et al.  Assessment of Hypercholesterolemia Control in a Managed Care Organization , 2001, Pharmacotherapy.

[17]  C. Ballantyne,et al.  Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. , 2000, Archives of internal medicine.

[18]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[19]  Sidney C. Smith,et al.  Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. , 1999, The American journal of cardiology.

[20]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[21]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[22]  Barry J. Davis,et al.  Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial , 1998, Annals of Internal Medicine.

[23]  M. Bala,et al.  Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. , 1998, The American journal of cardiology.

[24]  R L Brown,et al.  Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. , 1998, Archives of internal medicine.

[25]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.